宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

收市竞价 09-30 16:00:09

3.455

+0.105

+3.13%

最高3.485	最低3.240	成交量15.18万
今开3.475	昨收3.350	日振幅7.31%
总市值14.82亿	流通市值14.44亿	总股本4.29亿
成交额51.81万	换手率0.04%	流通股本4.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.455,"timestamp":1790755200005,"preClose":3.35,"halted":0,"volume":151800,"delay":0,"changeRate":0.03134328358208954,"floatShares":418000000,"shares":429000000,"eps":-0.6199938020743437,"marketStatus":"收市竞价","change":0.105,"latestTime":"09-30 16:00:09","open":3.475,"high":3.485,"low":3.24,"amount":518054,"amplitude":0.073134,"askPrice":3.475,"askSize":1400,"bidPrice":3.455,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.6343472434921781,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790755800000},"marketStatusCode":4,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.35,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":0.491815,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"1106554614","title":"宜明昂科-B回购70,600股股份，涉资约23.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106554614","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106554614?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:46","pubTimestamp":1790682376,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年9月29日公告称，公司于香港联合交易所回购70,600股H股，占该公司回购前已发行股份总数约0.0169%。本次回购价格区间介乎每股3.265港元至3.415港元，总耗资约23.69万港元。根据此前获得的回购授权，宜明昂科生物医药技术（上海）股份有限公司可回购最多43,150,769股。公司确认是次回购已获董事会正式批准，并已遵守香港联合交易所上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购70,600股股份，涉资约23.69万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671287219","title":"宜明昂科-B(01541)9月29日斥资23.69万港元回购7.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671287219","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671287219?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:44","pubTimestamp":1790682292,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年9月29日斥资23.69万港元回购7.06万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671473291","title":"港股异动 | 宜明昂科-B(01541.HK)涨超6% IMM0306重磅Ib/IIa期临床数据披露 有望成为增厚利润关键一环","url":"https://stock-news.laohu8.com/highlight/detail?id=2671473291","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671473291?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:43","pubTimestamp":1790667788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157035185","title":"宜明昂科-B完成50百万元子公司增资 继续持股68.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157035185","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157035185?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:45","pubTimestamp":1790606742,"startTime":"0","endTime":"0","summary":"2026年9月28日，宜明昂科生物医药技术（上海）股份有限公司发布自愿公告称，其对子公司宜明凯尔生物医药技术（上海）有限公司的增资及相关工商登记手续已全部完成。根据公告，投资者已按照增资协议向目标公司注入对价人民币50百万元。目标公司仍为宜明昂科-B的非全资附属公司，其财务业绩将继续并入集团财务报表。本次增资事项最初于2026年8月7日公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670255434","title":"宜明昂科-B(01541)附属宜明凯尔生物医药技术(上海)完成增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2670255434","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670255434?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:40","pubTimestamp":1790606412,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，内容有关附属宜明凯尔生物医药技术(上海)获增资5000万元。于本公告日期，增资及有关增资的相关工商登记程序已完成。投资者已根据增资协议完成支付人民币5000万元的对价。增资完成后，目标公司宜明凯尔生物医药技术(上海)有限公司分别由公司、嘉兴昶新、生科起航、新界创元及王先生持有约68.34%、15.83%、6.33%、6.33%及3.17%股权。因此，目标公司仍为公司非全资附属公司，且其财务业绩继续并入集团财务报表。目标公司主要从事开发代谢性疾病及罕见病创新药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","161726","BK4581","01541","399441","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177951173","title":"宜明昂科-B 2026年中期营收2,542.40万元，经调整净亏损1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177951173","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177951173?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:33","pubTimestamp":1790606029,"startTime":"0","endTime":"0","summary":"2026年上半年，宜明昂科-B实现营收2,542.40万元，同比下降33.20%。公司同期实现经调整净亏损1.62亿元，同比扩大12.50%。\n从成本端看，报告期内，研发费用为1.55亿元，同比下降7.90%，主要由于部分临床前与生产开支减少所致；管理开支为2,319.10万元，同比下降14.90%。经营活动所用现金净额为1.60亿元，同比上升22.20%。\n在分业务方面，合作开发收入2,525.20万元，同比下降33.50%；测试服务收入15.80万元，与去年同期持平；细胞株及其他产品收入1.40万元，同比下降56.30%。公司将继续推进核心在研项目的临床与商业化进程，进一步夯实研发管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 2026年中期营收2,542.40万元，经调整净亏损1.62亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669458554","title":"宜明昂科-B(01541)：新一代MCE分子，重磅Ib/IIa期临床数据披露，再次确认IMM0306差异化创新优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2669458554","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669458554?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:31","pubTimestamp":1790213485,"startTime":"0","endTime":"0","summary":"在今年8月21日系统性红斑狼疮适应症获得美国FDA的IND许可后，宜明昂科-B自主研发的靶向CD47和CD20的双特异性分子阿沐瑞芙普α再次迎来一个里程碑利好。相较于已上市BTK抑制剂的ORR 57.8%和CRR 12%，IMM0306联合来那度胺方案有望为MZL患者提供更加高效的治疗选择。结语随着此次IMM0306在两项适应症上的重磅数据披露，让宜明昂科在差异化原研创新方面的确定性得到进一步确认。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187681225","title":"宜明昂科-B9月16日回购9.24万股股份，耗资约29.76万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187681225","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187681225?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:52","pubTimestamp":1789555968,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年9月16日公布翌日披露报表，披露最新回购交易信息。公司于当日于香港联合交易所场内回购合计92,400股H股，占公司现有已发行股份总数的约0.0221%。回购价范围介乎每股3.155港元至3.27港元，回购数量对应的成交量加权平均价为每股3.2205港元，合计支付金额约29.76万港元。回购完成后，宜明昂科-B已发行股份为418,205,105股，库藏股数增至2,272,200股，公司整体已发行股份总数维持于420,477,305股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B9月16日回购9.24万股股份，耗资约29.76万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667076446","title":"宜明昂科-B(01541)9月16日斥资29.76万港元回购9.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667076446","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667076446?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:50","pubTimestamp":1789555805,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年9月16日，该公司斥资29.76万港元回购9.24万股股份，每股回购价3.155-3.27港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167978102","title":"宜明昂科-B回购5.52万股，耗资约17.76万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167978102","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167978102?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:32","pubTimestamp":1789122748,"startTime":"0","endTime":"0","summary":"宜明昂科-B于2026年9月11日公告，已在香港联交所场内回购H股55,200股，占当日已发行股本约0.0132%，每股回购价介乎3.175港元至3.29港元，合计支付约17.76万港元。\n回购完成后，该公司已发行股本（不含库存股）减少至418,297,505股，库存股数量增至2,179,800股，合计股本总数为420,477,305股。公司于2026年5月28日通过的回购授权可回购股份总数为43,150,769股，截至目前已回购2,179,800股，占授权通过日已发行股本的0.505%。\n公司确认已遵守香港联交所主板上市规则及相关法律法规，公告由执行董事、联席公司秘书关梅签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购5.52万股，耗资约17.76万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666257635","title":"宜明昂科-B(01541)9月11日斥资17.76万港元回购5.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666257635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666257635?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:27","pubTimestamp":1789122454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年9月11日，该公司斥资17.76万港元回购5.52万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182449307","title":"宜明昂科-B回购5.80万股股份，耗资约19.61万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182449307","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182449307?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:17","pubTimestamp":1789035457,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年9月10日发布公告，披露近期在香港联交所场内回购股份事宜。公告显示，公司于2026年9月10日回购H股股份共58,000股，占该回购前公司已发行股本约0.0139%。每股回购价格介乎3.35港元至3.435港元，总耗资约19.61万港元。据悉，公司于2026年5月28日通过回购授权，总数为43,150,769股。截至本次回购，公司已累计购回2,124,600股，约占授权时已发行股本的0.492%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B回购5.80万股股份，耗资约19.61万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666625085","title":"宜明昂科-B(01541.HK)9月10日斥资19.61万港元回购5.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666625085","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666625085?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:14","pubTimestamp":1789035282,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193124077","title":"宜明昂科-B：9月4日回购4.48万股，耗资约15.54万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193124077","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193124077?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:46","pubTimestamp":1788518804,"startTime":"0","endTime":"0","summary":"2026年9月4日，宜明昂科生物医药技术（上海）股份有限公司发布公告，宣布当日于香港联交所场内回购H股44,800股，约占现有已发行股份0.0107%。本次回购价格区间为每股3.435港元至3.55港元，合计耗资155,424港元。回购完成后，公司已发行股份总数维持420,477,305股，其中库藏股增至2,066,600股。公司同时确认，本次股份回购已获董事会正式授权，并遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：9月4日回购4.48万股，耗资约15.54万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664366643","title":"宜明昂科-B(01541.HK)9月4日斥资15.54万港元回购4.48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664366643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664366643?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:39","pubTimestamp":1788518378,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169812923","title":"宜明昂科-B 2026年8月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1169812923","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169812923?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:56","pubTimestamp":1788512181,"startTime":"0","endTime":"0","summary":"宜明昂科-B于2026年9月4日发布2026年8月股份变动月报表。报告显示，截至2026年8月31日，公司总注册股本为人民币431,507,695元，与上月底相比保持不变。根据公告，宜明昂科-B在本期内未发行新股、也未进行股份购回或注销操作。公司未开展任何新的股份期权或股权激励计划相关活动。公司表示，已符合香港联交所规定的最低公众持股量要求。该份月报表由公司执行董事、联席公司秘书关梅签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004094","title":"宜明昂科-B(01541.HK)：提名刘秀枝担任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662004094?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:33","pubTimestamp":1787931233,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154767258","title":"宜明昂科-B（01541）拟更换独董 朱禎平辞任、刘秀枝获提名接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1154767258","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154767258?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:15","pubTimestamp":1787926542,"startTime":"0","endTime":"0","summary":"2026年8月28日，宜明昂科生物医药技术（上海）股份有限公司发布公告称，公司董事会收到独立非执行董事朱禎平博士的辞任申请，理由为其需投入更多时间于其他商业事务。朱博士将继续履行相关职务直至股东大会选举出新任独立非执行董事之日，届时其辞任即时生效，并同时卸任董事会审计委员会、薪酬委员会及提名委员会成员。公司董事会确认，朱博士与董事会无意见分歧，亦无任何需提请香港联合交易所有限公司或股东注意的其他事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196464406","title":"宜明昂科-B（01541）披露IMM2510联合IMM27M一线治疗晚期肝细胞癌II期临床试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1196464406","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196464406?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:22","pubTimestamp":1787836942,"startTime":"0","endTime":"0","summary":"2026年8月27日，宜明昂科生物医药技术（上海）股份有限公司发布自愿公告称，IMM2510联合IMM27M一线治疗晚期肝细胞癌的II期临床试验已完成首例患者给药。该研究主要评估该联合疗法在HCC患者中的初步疗效与安全性。公司自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，临床开发进展稳定。根据香港联交所证券上市规则第18A.05条的警示声明，公司无法保证能够成功开发或最终上市销售IMM2510联合IMM27M。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008845","title":"宜明昂科-B(01541)：IMM2510联合IMM27M一线治疗晚期HCC的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662008845?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:21","pubTimestamp":1787836891,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM2510联 合 IMM27M一线治疗晚期肝细胞癌患者的II期临床试验顺利完成首例患者给药。该研究旨在评估IMM2510联合IMM27M在该患者群体中的初步疗效及安全性。自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，该联合疗法的临床开发稳步推进，并展现出卓越的潜力。令人鼓舞的早期临床结果证实，IMM2510联合IMM27M在晚期实体瘤治疗中具有显著的抗肿瘤活性及可控的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","MDTX","IBBQ","BK1161","PSYK","BK4006","IBBJ","01541","COAL","HCC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.003},{"period":"1month","weight":-0.097},{"period":"3month","weight":-0.1344},{"period":"6month","weight":-0.2947},{"period":"1year","weight":-0.7452},{"period":"ytd","weight":-0.4254}],"compareEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.0789},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.125053},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.059944},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.036378},{"month":4,"riseRate":0.666667,"avgChangeRate":0.020918},{"month":5,"riseRate":0.333333,"avgChangeRate":0.218025},{"month":6,"riseRate":0.333333,"avgChangeRate":0.064638},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.092027},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.068233},{"month":9,"riseRate":0.666667,"avgChangeRate":0.048007},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.115476},{"month":11,"riseRate":0,"avgChangeRate":-0.146508},{"month":12,"riseRate":0,"avgChangeRate":-0.128943}],"exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}